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1. Introduction 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage or described in terms of such a damage” (Merskey et al., 1986). It 
is a pivotal and the most impairing symptom in rheumatic diseases (Edwards et al., 2009; 
Fitzcharles et al., 2005; Sokka, 2003). Most patients consulting a rheumatologist suffer pain 
(Fitzcharles et al., 2005). Chronic pain influences physical and psychological status and 
causes impairment of quality of life as well as work disability (Dhanani et al., 2002; Kroenke 
et al., 2009; Skevington, 1998). For rheumatologists the assessment and treatment of pain is 
an integral part of daily patient care. Although remission of rheumatic diseases can be 
achieved with therapy with disease-modifying anti-rheumatic drugs (DMARDs) or 
biological pain can be still a troubling symptom. Pain is influenced by multiple factors such 
as genetics, experience, cultural and social background and psychological conditions (Gerez-
Simon et al., 1989; Martinez et al., 1995; Mogil, 1999). Comorbid depression is associated 
with inflammation and worsens experience of pain (Kojima et al., 2009). Pain perception 
enhances the elevation of pro-inflammatory cytokines and activates a cascade of 
neurohumoral processes which can be dysregulated in patients with rheumatic diseases 
(Bingham et al., 2009; Edwards et al., 2009; Fitzcharles et al., 2005).  
2. Types of pain and pathophysiology of pain in rheumatic diseases 
Pain perception and the development of chronic pain is a complex process of neural 
integration implying response of peripheral tissue damage and transduction of information 
in peripheral and central nervous system (Bingham et al., 2009). Adequate pain 
management requires subtile differentiation of rheumatic pain. Pain can be divided into 
various classifications depending on anatomical origin in the musculoskeletal system or 
special aspects in pathophysiology. Articular pain is distinguished from extra-articular pain 
which can be subdivided into muscular/musculotendinous or neurogenic pain. Muscular 
pain is caused by muscle stress due to protective posture, impaired joint-function or 
malposition, myositis or cortisone-induced myopathy. Neurogenic compression syndromes 
or entrapement syndromes induce neurogenic pain (Engel, 2008). Figure 1 demonstrates 
differentiation of rheumatic diseases depending on pain localization and systemic 
inflammatory response. Tissue damage and chronic inflammation is not solely responsible 
for pain perception in rheumatic diseases. Chronic rheumatic pain can also be categorized 
into nociceptive/inflammatory, peripheral neuropathic and central neuropathic/functional 
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pain (Goldenberg, 2010; Goldenberg et al., 2011; Winfield, 2008). Due to complex 
pathophysiology rheumatic pain is often of mixed type and the concept of central 
neuropathic pain is currently the focus of research, in particular in chronic pain syndromes 
like fibromyalgia and chronic low back pain. Classical nociceptive pain pathway/sensation 
starts with depolarization of A and C fibers acting as primary afferent neurons (Bingham et 
al., 2009). Tissue damage as occurring in systemic inflammatory or degenerative rheumatic 
diseases as well as localized tenosynovitis, bursitis or arthritis can induce firing of 
peripheral neurons (Winfield, 2008). Nociceptors activate ascending dorsal horn neurons 
(lateral and medial spinothalamic tract) which transfer the signal to brainstem and thalamus 
thereby projecting to the somatosensory cortex, hypothalamus and limbic system (Bingham 
et al., 2009; Goldenberg, 2010; Schaible et al., 2006). Afferent sensory neurons induce the 
release of neurotransmitters such as glutamate, substance P and -aminobutyric acid (GABA) 
in the dorsal horn influencing pain transmission (Bingham et al., 2009; Fitzcharles et al., 2005; 
Goldenberg, 2010). Interneurons and descending spinal pathways like periaqueductal gray, 
serotonergic as well as noradrenergic systems modulate the pain pathway. Cannabinoid 
receptors and opioid receptors have inhibitory effects (Bingham et al., 2009). Despite dense 
sensory and sympathetic innervation of joint capsules, ligaments, menisci, periosteum, 
synovial blood vessels and subchondral bone normal joints are not innervated (Fitzcharles et 
al., 2005). In inflammation primary afferent neurons are sensitized and silent nociceptors 
start firing (Bingham et al., 2009; Fitzcharles et al., 2005; Schaible et al., 2006). Their 
activation threshold decreases and they are activated even by gentle and nonpainful stimuli. 
This process is called peripheral sensitization (Bingham et al., 2009; Edwards et al., 2009; 
Fitzcharles et al., 2005). Inflammatory molecules such as prostanoids, TNF, chemokines, 
kinins and growth factors are produced in damaged tissue and stimulate primary afferent 
neurons (Bingham et al., 2009; Fitzcharles et al., 2005). Vice versa activated peripheral 
neurons release inflammatory mediators. This neurogenic inflammation maintains a 
“vicious circle” of persistent activation of nociceptive and immune system causing chronic 
rheumatic pain (Goldenberg et al., 2011). TNF has neurostimulatory properties by inducing 
upregulation of expression of substance P in the central nervous system (Grassi et al. 1994; 
Tonussi & Ferreira, 1999). Persistent activation of nociceptors and increasing production of 
neurotransmitters and prostanoids results in central sensitization especially in sensory 
neurons of the dorsal horn (Bingham et al., 2009; Fitzcharles et al., 2005; Goldenberg, 2010; 
Schaible et al., 2006). Sustained local inflammation induces peripheral and central 
sensitization as well as pathological nerve growth with innervation of cartilage contributing 
to development of chronic pain in rheumatic diseases (Kidd & Urban, 2001; Niissalo, 2002). 
Furthermore tissue damage or entrapment can affect nociceptors and peripheral 
neuropathic pain can develop (Bingham et al., 2009; Goldenberg, 2010; Schaible et al., 2006). 
Patients complain of electrical sensations, burning pain, coldness, numbness or itching. In 
rheumatoid arthritis chronic inflammation denervates the synovium and may cause 
neuropathic pain or sensations of joint swelling (Bingham et al., 2009). Central neuropathic 
pain former known as functional pain is characterized by chronic widespread pain in 
different regions of the body as observed in fibromyalgia. Usually no structural 
abnormalities can be identified. This type of pain is often accompanied by symptoms like 
fatigue, depression, sleep disturbance and memory difficulties. Dysfunction in central 
nervous system and imbalance of neurotransmitters like norepinephrine, γ-aminobutyric 
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Fig. 1. Types of pain (Engel, 2008) 
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acid (GABA), serotonin, glutamate, and substance P can cause augmented central pain 
processing (Goldenberg et al., 2011). Functional neuroimaging studies could reveal that 
patients with central pain exhibit increased activity in brain regions involved in pain 
processing compared to healthy individuals (reviewed in Goldenberg et al., 2011). The 
stress-induced increase of cytokines like TNF could account for higher pain levels in 
patients with depression and anxiety (Dickens, 2002). Genetic and environmental factors like 
early life trauma, physical trauma, infections or emotional stress can contribute to the 
development of central neuropathic pain (Goldenberg et al., 2011). Central neuropathic pain 
is not only observed in patients with chronic pain syndromes like fibromyalgia but also seen 
in patients with osteoarthritis and rheumatoid arthritis (Hochman et al., 2010; Wendler et 
al., 2001). Patients with ankylosing spondylitis, psoriatic arthritis or osteoarthritis have a 
higher pain threshold compared with those of rheumatoid arthritis underlining the concept 
of sustained inflammation and pain perception in rheumatoid arthritis (Buskila et al., 1992; 
Gerecz-Simon et al., 1989). Allodynia or hyperalgesia are common sensations in patients 
with rheumatic diseases. Hypersensitivity to stimuli like gentle touching which are usually 
nonpainful is called allodynia. Hyperalgesia is defined as increased pain sensation due to 
lower pain threshold. The underlying pathophysiological factors are proposed to be changes 
in central pain processing and enhanced reactivity of immune mediators as seen in central 
and peripheral sensitization (Engel, 2008; Goldenberg et al., 2011; Winfield, 2008). Pain 
perception differs between rheumatic diseases and between individuals suffering from 
equal diseases making it difficult and challenging to distinguish the types of pain and to 
treat patients properly. The current concept of chronic rheumatic pain implies a complex, 
multifactorial pathophysiological model with nociceptive and neuropathic pain components 
called “mixed pain”. 
3. Pain assessment 
Assessment of pain is required before the initiation of treatment to record efficacy of 
therapy (Fitzcharles et al., 2005; Sokka, 2003; Wendler, 2010). The patient`s pain report is 
subjective and depends on emotion, cognition and behavior (Fitzcharles et al., 2005; 
Kojima et al., 2009; Sokka, 2003). Self-reporting questionnaires provide qualitative and 
quantitative assessment of pain and are validated for research purposes as well as for 
documentation of disease activity and effectiveness of therapy (Sokka, 2003). Pain 
assessment should be integrated in daily practice of rheumatologists during interview and 
examination and includes verbal and nonverbal communication such as movements and 
facial expression of the patients. Verbal rating scales, numeric rating scales, visual 
analogue scales or pictogram analogue scales have become widely used in clinical care 
(Sokka, 2003; Wendler, 2010). The pain visual analogue scale (VAS) is a reliable method 
for assessing the intensity of pain (Jensen et al., 1998; Sokka, 2003; Wendler, 2010). It is 
integrated in The Health Assessment Questionnaire (HAQ), a valid instrument for the 
measurement of functional disability, pain and global status (Fitzcharles et al., 2005; 
Sokka, 2003). The 10 cm scale is bordered on each side. The spectrum of pain ranges 
across a continuum from 0 (no pain) to 10 (very severe pain). In the numeric rating scale 
numbers describe the pain severity, therefore results are comparable for follow up. Figure 
2 shows the visual analogue and the numeric rating scale. 
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Fig. 2. Pain scales 
When analyzing pain scores physicians should take into account various rheumatic diseases. 
In rheumatoid arthritis pain scores correlate with radiographic and laboratory results 
whereas fibromyalgia patients suffer severe pain in the absence of structural damage 
(Sokka, 2003). The first consultation of patients with pain should include a detailed 
interview and neurological and musculoskeletal examination of the patient (American 
Society of Anesthesiologists, 2010; Fitzcharles et al., 2005). A general medical history and 
history about the onset, quality, intensity, distribution and duration of pain, ameliorating 
and aggravating factors, symptoms, social and psychological impacts as well as previous 
therapies should be evaluated (American Society of Anesthesiologists, 2010). Body schemes, 
e.g. in the McGill pain questionnaire, facilitate the assessment of patients with chronic 
rheumatic diseases suffering from pain in various parts of the body (Wendler, 2010). Pain 
diaries can activate patients to document pain character and its influence in motion and 
function as well as to recognize effectiveness of treatment (Wendler, 2010).  
4. Pain therapy in rheumatic diseases 
Once the rheumatologist has assessed the patient`s pain an adequate therapy has to be 
initiated. Optimal pain management should encompass multimodal interventions with 
pharmacological and non-pharmacological treatment strategies (American Society of 
Anesthesiologists, 2010; Fitzcharles et al., 2005). Non-pharmacological procedures include 
education, psychological care, physical and/or occupational therapy as well as joint 
protection and/or surgery. 
4.1 Non-pharmacological pain treatment 
Education has a tremendous effect on sufficient pain control in patients with rheumatic 
diseases. Information about the disease and therapeutic options can reduce the fear of long 
term consequences, such as loss of function, joint damage, chronic pain, and implications on 
social and family life. Self-management strategies provide patients with a wide range of 
www.intechopen.com
 
Insights and Perspectives in Rheumatology 
 
246 
possibilities to influence their course of the disease. Exercise, joint protection techniques and 
appropriate use of pharmacological pain therapy encourage patients to cooperate with their 
attending physician (Goldenberg et al., 2011). 
For sufficient pain control the psychological status of the patient has to be evaluated (Kojima 
et al., 2009). Depression can worsen the perceived pain. Therefore rheumatoid arthritis 
patients describing severe pain without active disease could benefit from psychological 
therapy (Kojima et al., 2009). Additional cognitive behavioral therapy, biofeedback, 
relaxation training and self-care education can improve the patient`s well-being (American 
Society of Anesthesiologists, 2010; Kimura & Walco, 2007).  
Patients with rheumatic diseases are often physically inactive. Physiotherapy and exercise 
programs support mental and physical health (Kimura & Walco, 2007; Roddy et al., 2005). 
Patients with rheumatic diseases should always be encouraged to get exercise. Due to 
chronic pain they often feel weak and fatigue causes impaired activity. On the one hand 
patients fear exacerbation of musculoskeletal pain when moving. Consequently avoidance 
of exercise deteriorates muscle strength and physical condition. On the other hand excessive 
exercise aggravates fatigue and flares can occur. Mild exercise like walking, water aerobics, 
and bicycling, being appropriate for age and condition, can support physical fitness and 
comfort (Winfield, 2008). Physical therapy with heat or cold can reinforce therapeutic 
effects. In particular in nociceptive pain application of moderate heat (e.g. paraffin, packs, 
hydrotherapy) can improve pain control. In generalized pain syndromes sauna, baths, 
showers or hot mud can be effective. Cold therapy (e.g. packs, sprays or immersion) is 
recommended in acute pain states as seen in flares of rheumatic diseases (Winfield, 2008). 
Transcutaneous electrical nerve stimulation (TENS) is an independent option of physical 
therapy at home. 
Synovectomy and arthroplasty are therapeutic options in patients with continuous pain, 
joint deformity and functional loss (Kimura & Walco, 2007). The role of complementary 
therapies in pain management needs to be further examined (Fitzcharles et al., 2005). For 
optimal pain management a combination of different medications is often necessary. 
Rheumatologists have to prove efficacy of therapy and compliance of the patient. 
Discontinuation of treatment is required if side effects occur or if the therapy is ineffective.  
4.2 Pharmacological pain treatment 
Intra-articular injections, topical applications, selective and non-selective non-steroidal anti-
rheumatic drugs (NSAIDs), opioids as well as adjuvant drugs are therapeutic options for 
pain control. DMARDs like methotrexate, sulfasalazine, leflunomide and biologicals are 
prescribed to reduce disease activity and to maintain remission. Reduced disease activity is 
associated with improved functional status and reduced pain (Kimura & Walco, 2007). 
However, pain remains to be a leading symptom in patients with rheumatic diseases. Due to 
serious side effects of long-term application high dose corticosteroids should only be 
prescribed in severe, life-threatening disease. Intra-articular injections can help to reduce 
localized joint inflammation and pain (Kimura & Walco, 2007). The number of injections is 
limited to three per year (Bernau & Heeg, 2003). Avoidance of systemic side effects is an 
advantage of topical analgesics such as capsaicin or topical NSAIDs like diclofenac, 
ibuprofen, ketoprofen, and piroxicam. Although plasma concentration is low after 
www.intechopen.com
 
Pain in Rheumatic Diseases 
 
247 
absorption local application can reduce mild to moderate pain in arthritis (Kroenke et al., 
2009; Mason et al., 2004).  
4.2.1 Non-selective and selective cyclooxygenase inhibitors 
Non-selective and selective cyclooxygenase inhibitors (coxibs) are potent analgesics with anti-
phlogistic properties and are successfully used in the treatment of degenerative and 
inflammatory joint diseases (Schaible et al., 2006; Unger & Baerwald, 2010). Table 1 shows the 
most common selective and non-selective COX-inhibitors. Application of NSAID results in 
inhibition of prostaglandin synthesis which sensitizes nociceptors in inflamed joints and 
thereby causing pain in arthritis (Schaible et al., 2006; Unger & Baerwald, 2010). Furthermore 
central sensitization is followed by prostaglandin E2 (PGE2) release in the dorsal horns of the 
spinal cord (Bingham et al., 2009; Fitzcharles et al., 2005). However, gastrointestinal, renal, 
cardiovascular side effects and hepato-toxicity as well as platelet inhibition restrict their 
application (Kimura & Walco, 2007; Kroenke et al., 2009; Unger & Baerwald, 2010). Studies 
show that coxibs and traditional NSAIDs do not significantly differ in their cardiovascular side 
effects (reviewed in Luttosch & Baerwald, 2011; Unger & Baerwald, 2010). Therefore these 
agents should be administered in a low dose and for a short term only. Naproxen, paracetamol 
or opioids seem to be an option for pain control in patients with cardiovascular risk factors 
and should be preferred in these groups (Kroenke et al., 2009; Luttosch & Baerwald, 2011; 
Unger & Baerwald, 2010). Coxibs should be preferred in patients with risk of gastrointestinal 
complications due to their lower risk of developing a serious adverse event compared to non-
selective cyclooxygenase-inhibitors (Unger & Baerwald, 2010). In persons 60 years or older, in 
those with gastrointestinal symptoms and in patients taking corticosteroids or antiplatelet 
agents a proton pump inhibitor should be coadministered with traditional NSAIDs, or a coxib 
should be prescribed (Kroenke et al., 2009). 
 
Name Half-time Dose (mg) Peculiarity Contraindications 
Etoricoxib 
 
25 h 
 
OA 30-60 1/day 
RA/SpA 90 
1/day 
gout 120 1/day 
high blood pressure 
is a contraindication
peptic ulcers or GI-
bleeding 
cardio-
/cerebrovascular 
diseases 
arterial occlusive 
disease 
heart failure 
impaired liver 
function 
crea-clear. <30 
ml/min 
pregnancy 
breast-feeding 
Crohn`s disease 
Celecoxib 12 h OA 200 1-2/day 
RA 100-200 
2/day 
SpA 100-200 
2/day  
or 200-400 1/day 
allergy against 
sulfonamids is a 
contraindication 
Diclofenac 1-2 h 50-150/day in 2-4 
doses 
high cardio-vascular 
risk 
peptic ulcers, 
bleeding, perforation 
renal and liver 
failure 
Naproxen  14 h 500-1250/day in  
1-3 doses 
low cardio-vascular 
risc 
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Name Half-time Dose (mg) Peculiarity Contraindications 
Piroxicam 14-160 h 10-20/day severe skin reactions heart failure 
bone marrow 
dysfunction 
ASS-induced asthma 
Indometacin 2-3 h 50 1-3/day short term 
administration 
allergic reactions 
Acemetacin 4 h 30 1-3/day  
Ketoprofen 1,5-2,5 h 50 1-4/day or 
100 1-2/day 
phototoxic 
and allergic 
reactions 
Phenylbutazon 70 h 200 1-2/day SLE, pyrazol-allergy, 
thyroid gland 
dysfunction is a 
contraindication 
Meloxicam 20 h OA 7,5-15/day 
RA/SpA 15/day 
high COX-2- 
selectivity 
Ibuprofen 2-3 h max. 800-
1200/day 
no combination with 
ASS 
ASS-acetylsalicyl acid, COX-cyclooxygenase, crea-clear.-creatinine-clearance, GI-gastrointestinal, OA-
osteoarthritis, RA-rheumatoid arthritis, SLE-systemic lupus erythematodes, SpA-ankylosing spondylitis 
Table 1. Characteristics of typical NSAIDs and coxibs (Unger & Baerwald, 2010) 
4.2.2 Opioid therapy 
If NSAIDs are insufficient or contraindications and interfering side effects, respectively, 
exist opioids can be considered for effective pain control (Pierer et al., 2010). However, 
side effects and potential addiction have previously restricted their use in pain therapy. 
Therefore opioid therapy should only be prescribed within a multimodal pain control 
concept in advanced inflammatory or degenerative disease if other analgesics are 
ineffective (Pierer et al., 2010; Siegel et al., 2008). Long term, controlled and randomized 
studies concerning opioid use in rheumatic diseases are lacking. In clinical practice a 
positive effect on sleep and musculoskeletal function especially in neuropathic pain, 
rheumatoid arthritis, osteoarthritis and low back pain can be observed (Pierer et al., 2010; 
Siegel et al., 2008). Opioids bind to opioid receptors found in the central and peripheral 
nervous system (Kimura & Walco, 2007, Lang et al., 2010; Siegel et al., 2008). Studies 
confirm that opioids show mild anti-inflammatory effects (reviewed in Kimura & Walco 
2007). Endogenous opioid peptides are released in inflamed regions and bind to 
upregulated peripheral opioid receptors thereby controlling intrinsic pain pathways 
(Lang et al., 2010). Tramadol is a weak opioid beneficial especially in osteoarthritis, low 
back pain and fibromyalgia (Fitzcharles et al., 2005; Goldenberg et al., 2011; Kroenke et al., 
2009). Nausea, vomiting, constipation, dizziness, somnolence, cognitive impairment, 
urinary retention and respiratory depression are major undesirable adverse effects 
(American Society of Anesthesiologists, 2010; Lang et al., 2010; Winfield, 2008). Therefore 
long term therapy is not recommended. In chronic nonmalignant pain only mild pain 
reduction is observed whereas functional outcome (unemployment, necessity of health 
care) is declining (Siegel et al., 2008). Pain intensity, vital parameters, musculoskeletal 
function, possible addiction and side effects have to be controlled regularly (Pierer et al., 
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2010; Winfield, 2008). Upon initiation of opioids the dosage has to be titrated within the 
first two to three weeks (Winfield, 2008). After six weeks a significant pain reduction 
should be documented (Pierer et al., 2010). If optimal pain relief is not occurring opioid 
rotation should be considered (Kroenke et al., 2009). Exacerbation of pain should always 
be evaluated and the causes should be detected prior to increasing the dosage. If effective 
pain control does not occur after three months opioid therapy should be stopped. To 
avoid withdrawal symptoms a daily reduction of 10 % is strongly recommended (Pierer et 
al., 2010). Opioids should not be administered in patients with a history of or current 
substance use disorders (Kroenke et al., 2009). In older patients or patients with renal or 
liver function impairment the dose has to be reduced 25 % to 50 % (Kroenke et al., 2009; 
Winfield, 2008). Opioids should be administered with caution in older patients due to 
high risk of falls leading to fractures. There are insufficient data about the effect of long 
term therapy with opioids (Pierer et al., 2010). The WHO Three-Step Model for Pain 
Management provides an international accepted approach for effective pharmacological 
pain therapy and is demonstrated in Figure 3. The starting therapy step depends on the 
severity of pain. If the first treatment is insufficient the following step of the model should 
be initiated. Adjuvant drugs including antidepressants and anticonvulsants can be 
combined with the medications of the Three-Step Model.  
 
Fig. 3. WHO Three-Step Model of Pain management 
-"codeine" 
-"hydrocodone" 
-"antidepressants" 
-"anticonvulsants" 
-"dihydrocodeine" 
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4.2.3 Adjuvant drugs 
Tricyclic antidepressants like amitriptyline are the most commonly used adjuvant 
medications to treat patients with rheumatoid arthritis or ankylosing spondylitis 
(Fitzcharles et al., 2005). Adjuvant drugs play a major role in management of fibromyalgia 
and seem to be the most effective medications in this condition (Godfrey, 1996). Sleep, mood 
and fatigue are positively influenced. The anticonvulsants gabapentin and pregabalin 
provide pain relief especially in neuropathic pain (American Society of Anesthesiologists, 
2010; Kimura & Walco, 2007; Kroenke et al., 2009). They have neuromodulatory properties 
due to binding to calcium-channels in the central nervous system and inhibiting the release 
of neurotransmitters (American Society of Anesthesiologists, 2010; Kroenke et al., 2009). 
Cardiovascular side effects as well as somnolence or sedation can limit therapeutic 
application (American Society of Anesthesiologists, 2010; Kroenke et al., 2009). 
Antidepressants should be used with caution in older patients due to anticholinergic 
properties and the high risk of falls (Kroenke et al., 2009). Duloxetine and milnacipran 
interact with the serotonin and norepinephrine systems. Positive effects on pain und 
function could be demonstrated especially in fibromyalgia (Goldenberg et al., 2011). Figure 
4 shows a stepwise summary of pharmacological and non-pharmacological pain control in 
rheumatic diseases.  
 
Fig. 4. Pain therapy in rheumatic diseases (Winfield, 2008) 
4.2.4 Development of new medication 
Pharmacological pain management is restricted due to significant side effects or 
contraindications of NSAIDs and opioids. Development of new medication is in the focus of 
current research. Tapentadol hydrochloride is a µ-opioid-receptor agonist and 
norepinephrine reuptake inhibitor for the treatment of moderate and severe pain exhibiting 
less gastrointestinal side effects compared to traditional opioids and is effective in 
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neuropathic and/or inflammatory pain (Wade & Spruill, 2009). Cardiovascular and 
gastrointestinal side effects limit pain control with NSAIDs. Naproxcinod is a new 
developed COX inhibiting nitric oxide donator (CINOD) which shows an improved safety 
profile due to release of nitric oxide (NO) (Wallace et al., 2009). NO acts in the vasculature 
inducing positive effects on blood pressure and mucosal integrity in the gastrointestinal 
tract (Wallace et al., 2009). Further studies are needed to evaluate the role of dopaminergic 
agents, N-methyl-D-aspartate (NMDA) receptor antagonists,-aminobutyric acid (GABA) 
agonists, and 5-hydroxytryptamine 3 receptor antagonist in complex pain syndromes with 
central pain components (Goldenberg et al., 2011). 
5. Conclusion 
Pain is a cardinal symptom in patients with rheumatic disease. It impacts functioning, 
quality of life and causes disability. The pain is frequently multifactorial in origin and has 
both central and peripheral components. Disease activity is only marginally related to the 
extent of pain severity, and pain-related presentation can differ widely between individuals. 
Cognitions and emotions contribute to different perception of pain. Although remission of 
rheumatic diseases can be achieved with use of oral DMARDs or biological therapies, 
treatment of pain can be a challenge in every day practice. Assessment of pain is pivotal for 
monitoring therapy response and must take into account various factors. Non-
pharmacologic interventions, such as exercise and cognitive-behavioral therapy as well as 
the use of analgesics such as cyclooxygenase inhibitors or opioids should aim to achieve at 
better quality of life for patients with rheumatic diseases and should help to maintain 
function. 
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